Dogwood Therapeutics, Inc.

NASDAQ:DWTX

Biotechnology

Healthcare
$1.52 +2.22%

+$0.04 today

Market cap
$51.12M
Beta
1.76
P/E (TTM)
-0.2
EPS (TTM)
-$0.84
52W Low $1.28High $9.50

Volume 0.12M

Average 0.09M

DWTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Dogwood Therapeutics, Inc.NASDAQ: DWTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $2.67M rose 9.6% year over year, behind the +292.9% change in trailing-twelve-month research & development. Sequentially, it rose 14.2% from the prior quarter. Over 3 fiscal years it compounded at +39.4% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +9.6% toward the trailing-twelve-month pace of +292.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.67M+14.2% QoQ
Last fiscal yearDec 2025
$21.87M+519.3% YoY
LTMMar 2026
$22.1M+292.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.6%——
1 year+519.3%——
3-year CAGR+39.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
21.87M USD
Year-over-year change
+519.3%
4-year CAGR
+19.3%

Research & Development vs competitors

How DWTX compares with its peers on the latest reported figures

  • DWTX's LTM Mar 2026 research & development of $22.1M is the highest of the 2 companies compared; the peer median is $6.06M.
  • Its year-over-year change of +292.9% is the highest of 2, against a peer median of +141.7%.
  • Over three fiscal years its annual growth of +39.4% compares with a peer median of -35.0%.
DWTX Competitors Peer median
Research & Development for DWTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DWTXDogwood Therapeutics, Inc.LTM Mar 2026$22.1M +292.9%+39.4%—
EDSAEdesa Biotech, Inc.LTM Mar 2026$6.06M +141.7%-35.0%—
Peer median (excluding DWTX) $6.06M+141.7%-35.0%—

Competitors are the stored peer set for DWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development10.8M8.07M1.73M3.53M21.87M
Selling, General & Admin4.85M4.25M3.72M8.7M6.1M
Operating Expenses15.64M12.32M5.45M12.23M27.97M
Depreciation & Amortization00012.18K2.06K
EBITDA(15.96M)(12.25M)(5.3M)(12.25M)(34.03M)
EBITDA Margin—————
Operating Income(15.64M)(12.32M)(5.45M)(12.23M)(27.97M)
Operating Margin—————
Interest Income5.67K67.48K150.9K096.94K
Interest Expense00092.19K0
Other Income / Expenses(319.33K)67.48K150.9K(122.98K)(6.07M)
Income Before Tax(15.96M)(12.25M)(5.3M)(12.35M)(34.04M)
Pre-Tax Margin—————
Income Tax Expense000(503)221.1K
Net Income(15.96M)(12.25M)(5.3M)(12.35M)(34.26M)
Net Margin—————
EPS (Basic)(47.90)(27.66)(7.05)(12.52)(4.32)
EPS (Diluted)(47.90)(27.66)(7.05)(12.52)(4.32)
Weighted Avg Shares333.17K442.8K751.07K1.03M8.22M
Weighted Avg Shares (Diluted)333.17K442.8K751.07K1.03M8.22M

Dogwood Therapeutics, Inc.

NASDAQ:DWTX

Intrinsic Alpha fair value

Locked

Current Price

$1.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.